Liquid Biopsy Market by Blood, Urine, and Liquid Biopsy from 2023 to 2033
Liquid Biopsy Market Outlook for 2023 to 2033
The global Liquid Biopsy Market share is estimated to clock a revenue of USD 1,538.3 million in 2023. Our healthcare domain experts opine that liquid biopsy providers can expect a robust CAGR of 21.7% through 2033, with a forecast valuation of USD 10,938.6 million by 2033.
Governments of different economies with a rising cancer burden have pledged to support cancer research by offering sufficient funds for improved outcomes. For instance, according to the National Institute of Health (NIH), the National Cancer Institute was allocated USD 119 million by the federal government in the United States in 2021.
Researchers are continuously making new advancements in the biomarkers to detect and evaluate cancer by utilizing liquid biopsy. For instance, the development of new biomarkers for early cancer detection and subsequent treatment response.
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
Historical Growth of the Liquid Biopsy Market Vs. Forecast Outlook
Attributes
Details
Liquid Biopsy Market Size (2018)
USD 580.16 million
Liquid Biopsy Market Size (2022)
USD 1,264.3 million
Historical CAGR % (2018 to 2022)
21.5%
The liquid biopsy market registered a CAGR of 21.5% from 2018 to 2022. Over the forecast period, the growth rate is predicted to increase decimals, resulting in 21.7% through 2033. As cancer continues to affect many people, with the present figures predicted to escalate over the next decade, the demand for cancer detection tests like liquid biopsy is expected to have practical application, given that new and efficient technologies are being explored. Mentioned below are the few factors that are contributing to market growth:
Increasing government-led initiatives are predicted to motivate cancer specialists worldwide to set research goals in cancer treatments, focusing on convenience, affordability, and optimal patient care.
An upsurge in funding is anticipated to permit experts to create research alliances to facilitate improvements against several cancer outcomes.
Quick approvals for non-invasive cancer diagnosis tests by regulatory bodies like the United States Food and Drug Administration (FDA) are creating opportunities for key players.
Historical CAGR % (2018 to 2022)
21.5%
Forecast CAGR % (2023 to 2033)
21.7%
Category-wise Insights
CTC Holds the Leading Share in the Liquid Biopsy Market
Leading Biomarker Type
CTC (Circulating Tumor Cells)
Market Share % (2023)
56.9
The CTC (Circulating Tumor Cells) is predicted to account for a market share of 56.9% in 2023. Key factors that are propelling the use of CTCs over other liquid biopsy approaches are as follows:
The cells in CTCs are intact, which makes them applicable to an extensive range of biomarkers like gene expression, protein expression, and DNA mutations.
Surging demand for biomarkers that help detect cancer at any stage of its development. Since CTCs can be isolated from cancer patients at any stage of their disease, they assist in detecting cancer at any stage.
An increase in healthcare professionals are deploying CTCs to check the effectiveness of cancer treatment. By examining CTCs over extended periods, doctors can find out the response of a patient’s cancer to treatment and bring modifications in the treatment course.
Improvements carried out in CTC detection technology are predicted to further fuel its preference among healthcare specialists in the future.
Blood Sample Type Holds an Unbeatable Market Share
Leading Sample Type
Blood
Market Share % (2023)
93.4
Blood sample type makes up for 93.4% of the overall market. Since blood samples taken from different body parts or at different intervals are easy to compare, they find a high utilization rate among healthcare professionals. Blood samples can be collected from patients of any age group and any health condition, which boosts its accessibility among patients. Thus, doctors and patients alike are increasingly opting for blood samples.
Get Brochure on Email
Almost 80% of our clients request uniquely tailored intelligence.
Country-wise Insights
Key Players to Benefit from the New Advancements in Liquid Biopsy in the United Kingdom
Country
The United Kingdom
Forecast CAGR % (2023 to 2033)
26.4%
The United Kingdom liquid biopsy market is predicted to expand at a remarkable CAGR of 26.4% through 2033. Over the forecast period, the following factors are predicted to propel such growth rate in the United Kingdom:
Favorable healthcare policies and increasing expenditure on the healthcare system are together, impelling a conducive environment for liquid biopsy key players.
Cancer patients are predicted to see a spike over the next decade. This is predicted to highlight the necessity for liquid biopsy to diagnose patients at the early stage.
The presence of world-renowned research institutes in the United Kingdom, like the National Institute of Medical Research and the University of Oxford, catalyzes new advancements in test and technology.
Favorable Regulatory Environment Attracting Key Players to China
Country
China
Forecast CAGR % (2023 to 2033)
29.7%
At present, China leads in terms of the sales rate of liquid biopsy tests. According to recent market research by FMI analysts, the China liquid biopsy market is predicted to observe a sensational CAGR of 29.7% through 2033. The following factors give a comprehensive look into such growth opportunities for key players:
The boom in cancer diagnostics as the country inhabits a significant proportion of the population showing symptoms of developing cancer. Therefore, surging healthcare professionals are prescribing cancer diagnostics to determine further tests and procedures.
The regulatory environment in China is in favor of quicker product approvals, thus motivating key players in their endeavor for product advancement.
Experienced technicians in China are available at a lower expense, which also creates a supportive environment for the growth of the liquid biopsy market in China.
High Cancer Rate in India Drawing Investments by Established Key Players
Country
India
Forecast CAGR % (2023 to 2033)
24.4%
As per the recent market survey by FMI's analysts, the India liquid biopsy market is estimated to register an impressive CAGR of 24.4% through 2033. Given below are the leading factors backing the demand for liquid biopsy:
Surging government initiatives to elevate cancer awareness are promoting the use of liquid biopsy.
Rising investigations in product development for improved precision and efficiency are creating a positive outlook for the liquid biopsy market.
The increasing incidence rate of cancer among the population residing in India. For instance, the National Cancer Registry found out that cancer incidences are predicted to reach 735,575 in males and 806,218 in females in the year 2025. This is expected to press the country's need for technologically advanced liquid biopsy systems.
An increase in biotech companies, both budding and established, are concentrating on bringing efficiencies in early diagnosis and advancements in cancer patient care and treatment. Thus, enhancing the scope of the liquid biopsy market in India.
Advancements in the Personalized Healthcare Treatment in Japan Augmenting Liquid Biopsy Market
Japan is a substantial market in Asia Pacific for liquid biopsy. The following factors propelling the deployment of liquid biopsy in the country:
The increase in projects in Japan to realize personalized cancer treatment is enhancing the demand for liquid biopsies in the country. For instance, in June 2020, the National Cancer Center Hospital East announced that it is going to launch ‘CIRCULATE-Japan’ project to create personalized cancer treatment via a liquid biopsy to test circulating tumor DNA in the blood of patients who have to go through surgery for colorectal cancer.
Key players in the country are aiming to develop a solution to offer advanced personalized healthcare. In March 2021, Chugai obtained approval for the use of FoundationOne Liquid CDx Cancer Genomic Profile, which is a comprehensive genomic profiling test to detect solid tumors.
Key Players are Seizing the Business Opportunities Presented by Australia Healthcare Scene
Country
Australia
Forecast CAGR % (2023 to 2033)
20.2%
The Australia liquid biopsy market is expected to register a CAGR of 20.2% through 2033. The following factors are predicted to fuel the market growth:
Increasing presence of biotechnology and medical device companies in the country.
Extensive deployment of advanced technology to effectively treat cancer patients, along with the rising incidences of cancer in Australia.
Surging innovations in liquid biopsy procedures and technologies are propelling the market scope of liquid biopsy.
Gain Insights into the Strategic Moves of Key Players
Market participants delivering liquid biopsy tests are planning on strategically collaborating with end users like diagnostic centers, hospitals, and cancer research institutes to invigorate their product offerings in the market.
Manufacturers are further predicted to enjoy proprietary benefits by coming into product development and industry research funding agreements, which assist in creating precision diagnosis methods for different types of cancers. On top of this, key players are gaining government approvals and patents for new technologies to maintain their competitive edge in the market.
New Developments Observed in the Liquid Biopsy Market
Biocept Inc., a prominent provider of molecular diagnostic services, in July 2021, obtained a South Korean patent for Primer-Switch technology. This technology finds mutations in circulating tumor DNA via real-time PCR and associated methods, which helps identify rare cancer biomarkers.
Janssen Global Services, LLC, in July 2021, gained FDA permission for DARZALEX FASPRO, along with dexamethasone and pomalidomide, for treating adult patients suffering from multiple myeloma. Thus strengthening the firm's product offerings.
Thermo Fisher Scientific Inc., in August 2022, introduced the first NGS-based tests to facilitate RNA and DNA input. The Ion Torrent Oncomine Myeloid MRD Assays (RUO) offer a complete and extremely sensitive myeloid measurable residual (MDR) assessment of bone marrow and blood samples.
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
Companies Operating in the Liquid Biopsy Market
BIOCEPT, INC.
Qiagen N.V.
Trovagene, Inc
Janssen Global Services, LLC
MDxHealth SA
Natera, Inc
F. Hoffmann-La Roche Ltd
Silicon Biosystems
Pathway Genomics Corporation
Sysmex Corporation
Others
Report Scope
Report Attribute
Details
Growth Rate
CAGR of 21.7% from 2023 to 2033
Expected Market Value (2023)
USD 1,538.3 million
Anticipated Forecast Value (2033)
USD 10,938.6 million
Base Year for Estimation
2022
Historical Data
2018 to 2022
Forecast Period
2023 to 2033
Quantitative Units
Revenue in USD million and CAGR from 2023 to 2033
Report Coverage
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered
Biomarker Type, Sample Type, Application Type, Region
Regions Covered
North America; Latin America; Western Europe; Eastern Europe; Asia Pacific Excluding Japan; Japan; The Middle East and Africa
Key Countries Profiled
The United States, Canada, Mexico, Brazil, Germany, Italy, France, The United Kingdom, Spain, Russia, Poland, China, Japan, South Korea, India, ASEAN, Australia and New Zealand, GCC Countries, South Africa
